Merck & Co Inc.

3 nov. 2026, 23:01 UTC

Merck & Co Inc declined during after-market trading, continuing a trend of three consecutive sessions finishing lower since Tuesday's close.

2 nov. 2026, 23:06 UTC

Merck & Co Inc is trading modestly higher in after-market hours, recovering from a low point and reaching a peak in its one-month range.

31 oct. 2026, 00:02 UTC

Merck & Co Inc shares are modestly lower in after-market trading, retracing some gains from earlier in the session while remaining above their 20-day moving average.

30 oct. 2026, 23:06 UTC

Merck & Co Inc shares are trading lower in after-market hours, fluctuating between slight losses and modest gains while remaining above their 20-day moving average.

29 oct. 2026, 23:03 UTC

Merck & Co Inc shares rose in after-market trading, supported by positive Phase 3 trial results and FDA priority review for sacituzumab tirumotecan.

28 oct. 2026, 23:02 UTC

Merck & Co Inc shares are trading higher in after-market hours, supported by a significant rise in the Pharmaceuticals sub-sector ahead of its earnings report.

27 oct. 2026, 23:41 UTC

Merck & Co Inc shares gained slightly in after-market hours, showing upward momentum, though they remain below their 20-day moving average.

26 oct. 2026, 20:03 UTC

Merck & Co. reported Phase 3 TroFuse-005 trial results showing sacituzumab tirumotecan reduced death risk by 32%, while FDA set a PDUFA date of June 15, 2027.

23 oct. 2026, 20:07 UTC

Merck & Co., Inc. faces scrutiny as Bronstein, Gewirtz & Grossman, LLC investigates claims following early leak of clinical trial results for a joint cancer vaccine with Moderna.

22 oct. 2026, 23:02 UTC

Merck & Co Inc trades modestly higher since Thursday's close.

21 oct. 2026, 23:51 UTC

Merck & Co Inc receives European Commission approval for KEYTRUDA in combination with Padcev for muscle-invasive bladder cancer, marking a significant regulatory milestone.

20 oct. 2026, 23:21 UTC

Merck & Co Inc shares are trading lower in after-market hours, reflecting a broader decline in the Pharmaceuticals sub-sector.

19 oct. 2026, 20:08 UTC

Merck & Co Inc shares fell as the company agreed to acquire Silence Therapeutics for approximately $1.3 billion, amid ongoing concerns over Keytruda's patent expiration.

16 oct. 2026, 23:52 UTC

Merck & Co Inc is seeing modest gains in after-hours trading, maintaining a position around the middle of its one-month trading range since Friday's close.

15 oct. 2026, 23:01 UTC

Merck & Co Inc's shares moved roughly flat during after-market hours, fluctuating within a routine range since Thursday's close, maintaining a stable position.

14 oct. 2026, 22:51 UTC

Merck & Co Inc shares advanced modestly higher during after-market hours on Wednesday, diverging from a recent trend of higher daily closes.

13 oct. 2026, 23:01 UTC

Merck & Co Inc will present first-time results from three pivotal clinical trials at the ESMO Congress 2026, scheduled for October 23-27 in Madrid.

12 oct. 2026, 23:46 UTC

Citigroup maintains Neutral rating on Merck & Co Inc and raises price target to $145, reflecting ongoing confidence in the company's performance and outlook.

9 oct. 2026, 23:05 UTC

Merck & Co Inc shares advanced in after-market trading on Friday, maintaining a stable position around the middle of their one-month range.

8 oct. 2026, 23:40 UTC

Merck & Co Inc is trading modestly lower in after-market hours, reflecting broader market trends and remaining below its 20-day moving average.

7 oct. 2026, 22:50 UTC

Merck & Co Inc is trading modestly lower in after-hours, continuing a downward trend and remaining below its 20-day moving average.

6 oct. 2026, 23:05 UTC

Merck & Co Inc is trading lower in after-market hours, remaining below its 20-day moving average and near the lower end of its one-month range.

5 oct. 2026, 23:05 UTC

Merck & Co Inc's shares rose in after-market trading on Monday, despite earlier declines during the session, and remain near the lower end of their one-month range.

2 oct. 2026, 23:00 UTC

Merck & Co Inc shares are trading modestly lower in after-market hours, continuing a downward trend amid broader market reactions to disappointing jobs data.

1 oct. 2026, 19:46 UTC

Merck & Co Inc shares fell, continuing a downward trend amid concerns over rising inflation and bond yields, while the State Street Health Care Select Sector SPDR also declined.

30 sept. 2026, 23:05 UTC

Merck & Co Inc presented results from its Phase 2b trial of MK-7240-012 for hidradenitis suppurativa, with the stock trading slightly lower in after-market hours.

29 sept. 2026, 23:05 UTC

Merck & Co Inc is trading lower in after-market hours, slightly down from Tuesday's close after a brief high shortly after 5:40 PM.

28 sept. 2026, 19:16 UTC

Merck has secured a global license for SPR2015 from SciBrunch for $400 million, with total potential value reaching $2.13 billion, while shares are trading roughly flat.

25 sept. 2026, 23:05 UTC

Merck & Co. has withdrawn its Biologics License Application for ifinatamab deruxtecan after the FDA indicated insufficient trial data, with shares trading lower in after-market hours.

24 sept. 2026, 23:30 UTC

Merck & Co Inc's stock traded modestly lower in after-market hours following the announcement of Phase 2b/3 BRUNELLO trial results for diabetic macular edema.